US EditionAnuncia Medical Receives FDA Breakthrough Device Designation for ReFlow® External Ventricular Drains (EVD)
Summary by PR Newswire
2 Articles
2 Articles
All
Left
Center
1
Right
Anuncia Medical Receives FDA Breakthrough Device Designation for ReFlow® External Ventricular Drains (EVD) - Phoenix Bioscience Core
Facebook Twitter LinkedIn Email Print Company Supporting Global and Local Initiatives Reducing the Impact of Hydrocephalus SCOTTSDALE, Ariz., March 20, 2025 /PRNewswire/ — Anuncia Medical, Inc. (“Anuncia”), a pioneering company in CSF management and neurocritical care, has received Breakthrough Device Designation from the FDA for its ReFlow® EVD, an innovative solution for external ventricular drains (EVDs) used to manage brain swelling and el…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
